CN107531796A - 识别AChE的T14肽的抗体 - Google Patents

识别AChE的T14肽的抗体 Download PDF

Info

Publication number
CN107531796A
CN107531796A CN201680021081.0A CN201680021081A CN107531796A CN 107531796 A CN107531796 A CN 107531796A CN 201680021081 A CN201680021081 A CN 201680021081A CN 107531796 A CN107531796 A CN 107531796A
Authority
CN
China
Prior art keywords
antibody
antigen
seq
binding fragment
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680021081.0A
Other languages
English (en)
Chinese (zh)
Inventor
苏珊·格林菲尔德
萨拉·加西亚-瑞茨
保罗·莫雷尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuro Bio Ltd
Original Assignee
Neuro Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro Bio Ltd filed Critical Neuro Bio Ltd
Publication of CN107531796A publication Critical patent/CN107531796A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
CN201680021081.0A 2015-03-27 2016-03-23 识别AChE的T14肽的抗体 Pending CN107531796A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1505239.2A GB201505239D0 (en) 2015-03-27 2015-03-27 Antibody
GB1505239.2 2015-03-27
GB1600871.6 2016-01-18
GB1600871.6A GB2541477A (en) 2015-03-27 2016-01-18 Antibody
PCT/GB2016/050804 WO2016156803A1 (en) 2015-03-27 2016-03-23 Antibody that recognises the t14 peptide of ache

Publications (1)

Publication Number Publication Date
CN107531796A true CN107531796A (zh) 2018-01-02

Family

ID=53178191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680021081.0A Pending CN107531796A (zh) 2015-03-27 2016-03-23 识别AChE的T14肽的抗体

Country Status (13)

Country Link
US (1) US10954306B2 (https=)
EP (1) EP3274371B1 (https=)
JP (1) JP7327897B2 (https=)
KR (1) KR102626626B1 (https=)
CN (1) CN107531796A (https=)
AU (1) AU2016240020B2 (https=)
BR (1) BR112017020769A2 (https=)
CA (1) CA2979972A1 (https=)
ES (1) ES2952723T3 (https=)
GB (2) GB201505239D0 (https=)
MX (1) MX392158B (https=)
RU (1) RU2729491C2 (https=)
WO (1) WO2016156803A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001419A (zh) * 2014-11-26 2017-08-01 神经生物有限公司 神经变性障碍
CN108699541A (zh) * 2016-01-28 2018-10-23 神经生物有限公司 癌症

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201705044D0 (en) * 2017-03-29 2017-05-10 Neuro-Bio Ltd Biomarker
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
GB202112831D0 (en) * 2021-09-09 2021-10-27 Neuro Bio Ltd Biomarker
GB202113941D0 (en) 2021-09-29 2021-11-10 Neuro Bio Ltd Skin biomarker
CN120187864A (zh) 2022-09-08 2025-06-20 神经生物有限公司 使用t14肽诊断阿尔茨海默症的侧向流装置
GB202308779D0 (en) * 2023-06-13 2023-07-26 Neuro Bio Ltd Aptamer
GB202308799D0 (en) 2023-06-13 2023-07-26 Neuro Bio Ltd Neurodegenerative disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035962A1 (en) * 1996-03-22 1997-10-02 Synaptica Limited Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator
WO2008135790A1 (en) * 2007-05-04 2008-11-13 Enkephala Limited Biologically active c-terminal fragment of acetylcholinesterase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1269201A1 (en) 2000-03-29 2003-01-02 Synaptica Limited Alpha 7 nicotinic receptor screening assays
GB0028578D0 (en) * 2000-11-23 2001-01-10 Synaptica Ltd Screening assays
GB0502068D0 (en) * 2005-02-01 2005-03-09 King S College London Screening method
JP5186372B2 (ja) * 2005-08-16 2013-04-17 ジェネンテック, インコーポレイテッド 細胞/組織においてgalnac−t14発現を試験することによるapo2l/trailに対するアポトーシス感受性
EP2203746B1 (en) * 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
CN101530162B (zh) * 2008-03-10 2011-11-23 北京大北农科技集团股份有限公司 一种新型蛋白饲料添加剂的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035962A1 (en) * 1996-03-22 1997-10-02 Synaptica Limited Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator
EP1270594A1 (en) * 1996-03-22 2003-01-02 Synaptica Limited Antibodies to peptide from a soluble fragment of acetylcholinesterase
WO2008135790A1 (en) * 2007-05-04 2008-11-13 Enkephala Limited Biologically active c-terminal fragment of acetylcholinesterase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATTHEW G. COTTINGHAM等: "The Intact Human Acetylcholinesterase C-Terminal Oligomerization Domain Is R-Helical in Situ and in Isolation, but a Shorter Fragment Forms â-Sheet-Rich Amyloid Fibrils and Protofibrillar Oligomers", 《BIOCHEMISTRY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001419A (zh) * 2014-11-26 2017-08-01 神经生物有限公司 神经变性障碍
CN107001419B (zh) * 2014-11-26 2022-02-25 神经生物有限公司 神经变性障碍
CN108699541A (zh) * 2016-01-28 2018-10-23 神经生物有限公司 癌症
CN108699541B (zh) * 2016-01-28 2025-02-11 神经生物有限公司 癌症

Also Published As

Publication number Publication date
GB201505239D0 (en) 2015-05-13
US20180051094A1 (en) 2018-02-22
US10954306B2 (en) 2021-03-23
EP3274371B1 (en) 2023-06-07
AU2016240020A1 (en) 2017-11-02
CA2979972A1 (en) 2016-10-06
ES2952723T3 (es) 2023-11-03
JP7327897B2 (ja) 2023-08-16
WO2016156803A1 (en) 2016-10-06
MX392158B (es) 2025-03-21
AU2016240020B2 (en) 2022-02-17
BR112017020769A2 (en) 2018-06-26
KR102626626B1 (ko) 2024-01-17
GB201600871D0 (en) 2016-03-02
RU2729491C2 (ru) 2020-08-07
GB2541477A (en) 2017-02-22
MX2017012397A (es) 2018-01-26
RU2017133649A3 (https=) 2020-02-17
JP2018516849A (ja) 2018-06-28
EP3274371A1 (en) 2018-01-31
RU2017133649A (ru) 2019-04-29
KR20170138414A (ko) 2017-12-15

Similar Documents

Publication Publication Date Title
JP7327897B2 (ja) Acheのt14ペプチドを認識する抗体
US11739140B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP7029415B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
CA2437453C (en) Conformationally abnormal forms of tau proteins and specific antibodies thereto
KR101831459B1 (ko) 올리고머 특이적 아밀로이드 베타 에피토프 및 항체
IL303638A (en) Tau binding compounds
WO2023143425A1 (zh) 改善认知障碍的方法
TWI734279B (zh) 抗α-突觸核蛋白抗體及其用途
US20230365665A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
US20220064271A1 (en) Methods for treating tauopathies
US20230025707A1 (en) Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same
RU2847366C1 (ru) Профилактический или терапевтический агент для лечения деменции
TW202434285A (zh) 與異常蛋白質之聚集體形成相關之疾病的預防或治療劑
WO2021242757A1 (en) Monocolonal antibodies against pathological tau, and methods using same
WO2022060236A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES
EA039569B1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180102